Point-of-care platelet function testing predicts bleeding in patients exposed to clopidogrel undergoing coronary artery bypass grafting: Verify pre-op TIMI 45 - A pilot study

Clinical Cardiology

Volumn 38, Issue 2, 2015, Pages 92-98

  Reed, Grant W ^a,b   Kumar, Amit ^c   Guo, Jianping ^a   Aranki, Sary ^a   Shekar, Prem ^a   Agnihotri, Arvind ^d   Maree, Andrew O ^e   McLean, Dalton S ^f   Rosenfield, Kenneth ^g   Cannon, Christopher P ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c BROWN UNIVERSITY   (United States)

^d ST ELIZABETH'S MEDICAL CENTER   (United States)

^e ST JAMES S HOSPITAL   (Ireland)

^f LeBauer Cardiology Associates   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; HEMOGLOBIN; ANTITHROMBOCYTIC AGENT; P2RY12 PROTEIN, HUMAN; PURINERGIC P2Y RECEPTOR ANTAGONIST; PURINERGIC P2Y12 RECEPTOR; TICLOPIDINE;

ADULT; ARTICLE; BLEEDING; CHEST TUBE; CLINICAL ARTICLE; CORONARY ARTERY BYPASS GRAFT; FEMALE; HEMATOCRIT; HUMAN; HYPOTHESIS; MALE; MIDDLE AGED; PILOT STUDY; PLATELET REACTIVITY; POINT OF CARE TESTING; PREOPERATIVE PERIOD; PROSPECTIVE STUDY; THROMBOCYTE FUNCTION; ADVERSE EFFECTS; AGED; ANALOGS AND DERIVATIVES; AREA UNDER THE CURVE; BLOOD; BLOOD CLOTTING PARAMETERS; CHEMICALLY INDUCED; CLINICAL TRIAL; DRUG EFFECTS; DRUG RESISTANCE; HEMORRHAGE; HOSPITAL INFORMATION SYSTEM; METABOLISM; MULTICENTER STUDY; PREDICTIVE VALUE; PROCEDURES; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; RISK FACTOR; THROMBOCYTE; TREATMENT OUTCOME; UNITED STATES;

AGED; AREA UNDER CURVE; BLOOD PLATELETS; CORONARY ARTERY BYPASS; DRUG RESISTANCE; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; POINT-OF-CARE SYSTEMS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2Y12; RISK ASSESSMENT; RISK FACTORS; ROC CURVE; TICLOPIDINE; TREATMENT OUTCOME; UNITED STATES;

EID: 84925635138     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22357     Document Type: Article

References (29)

1. Mehta RH, Roe MT, Mulgund J, et al. Acute clopidogrel use and outcomes in patients with non-ST-segment elevation acute coronary syndromes undergoing coronary artery bypass surgery. J Am Coll Cardiol. 2006;48:281-286.
2. Nijjer SS, Watson G, Athanasiou T, et al. Safety of clopidogrel being continued until the time of coronary artery bypass grafting in patients with acute coronary syndrome: a meta-analysis of 34 studies. Eur Heart J. 2011;32:2970-2988.
3. Hillis LD, Smith PK, Anderson JL, et al. 2011. ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2011;58:e123-e210.
4. Thukkani AK, Fonarow GC, Cannon CP, et al. Get With the Guidelines Steering Committee and Investigators. Quality of care for patients with acute coronary syndromes as a function of hospital revascularization capability: insights from Get With the Guidelines-CAD. Clin Cardiol. 2014;37:285-292.
5. Berger JS, Frye CB, Harshaw Q, et al. Impact of clopidogrel in patients with acute coronary syndromes requiring coronary artery bypass surgery: a multicenter analysis. J Am Coll Cardiol. 2008;52:1693-1701.
6. Herman CR, Buth KJ, Kent BA, et al. Clopidogrel increases blood transfusion and hemorrhagic complications in patients undergoing cardiac surgery. Ann Thorac Surg. 2010;89:397-402.
7. Kremke M, Tang M, Bak M, et al. Antiplatelet therapy at the time of coronary artery bypass grafting: a multicentre cohort study. Eur J Cardiothorac Surg. 2013;44:e133-e140.
8. Yusuf S, Zhao F, Mehta SR, et al; Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation [published corrections appear in N Engl J Med. 2001;345:1506 and 2001;345:1716]. N Engl J Med. 2001;345:494-502.
9. Ascione R, Ghosh A, Rogers CA, et al. In-hospital patients exposed to clopidogrel before coronary artery bypass graft surgery: a word of caution. Ann Thorac Surg. 2005;79:1210-1216.
10. Chu MW, Wilson SR, Novick RJ, et al. Does clopidogrel increase blood loss following coronary artery bypass surgery? Ann Thorac Surg. 2004;78:1536-1541.
11. Kapetanakis EI, Medlam DA, Petro KR, et al. Effect of clopidogrel premedication in off-pump cardiac surgery: are we forfeiting the benefits of reduced hemorrhagic sequelae? Circulation. 2006;113:1667-1674.
12. Price MJ, Coleman JL, Steinhubl SR, et al. Onset and offset of platelet inhibition after high-dose clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers. Am J Cardiol. 2006;98:681-684.
13. Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor vs clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation. 2009;120:2577-2585.
14. Price MJ, Teirstein PS. Dynamics of platelet functional recovery following a clopidogrel loading dose in healthy volunteers. Am J Cardiol. 2008;102:790-795.
15. Ferraris VA, Brown JR, Despotis GJ, et al. Society of Thoracic Surgeons Blood Conservation Guideline Task Force. 2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. Ann Thorac Surg. 2011;91:944-982.
16. Ferraris VA, Saha SP, Oestreich JH, et al. 2012 update to the Society of Thoracic Surgeons guideline on use of antiplatelet drugs in patients having cardiac and noncardiac operations. Ann Thorac Surg. 2012;94:1761-1781.
17. Price MJ. Bedside evaluation of thienopyridine antiplatelet therapy. Circulation. 2009;119:2625-2632.
18. Price MJ, Berger PB, Teirstein PS, et al. GRAVITAS Investigators. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial [published correction appears in JAMA. 2011;305:2174]. JAMA. 2011;305:1097-1105.
19. Price MJ, Endemann S, Gollapudi RR, et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J. 2008;29:992-1000.
20. Patti G, Nusca A,Mangiacapra F, et al. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention: results of the ARMYDA-PRO (Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Platelet Reactivity Predicts Outcome) study. J Am Coll Cardiol. 2008;52:1128-1133.
21. Devlin TF, Weeks BJ. Spline functions for logistic regression modeling. In: Proceedings of the 11th Annual SAS Users Group International Conference. Cary, NC: SAS Institute, Inc.; 1986:646-651.
22. Gardner MJ, Altman DG. Statistics with Confidence. London, UK: British Medical Journal Publishing Group; 1989.
23. Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3:32-35.
24. Sharma S, Bhambi B. Use of platelet transfusion to facilitate surgery in patients on clopidogrel and aspirin therapy after drug-eluting stent percutaneous coronary intervention. Catheter Cardiovasc Interv. 2012;79:498-500.
25. Mangiacapra F, Patti G, Barbato E, et al. A therapeutic window for platelet reactivity for patients undergoing elective percutaneous coronary intervention: results of the ARMYDAPROVE (Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Platelet Reactivity for Outcome Validation Effort) study. JACC Cardiovasc Interv. 2012;5:281-289.
26. Patti G, Pasceri V, Vizzi V, et al. Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding Study). Am J Cardiol. 2011;107:995-1000.
27. Varenhorst C, James S, Erlinge D, et al. Assessment of P2Y(12) inhibition with the point-of-care deviceVerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin. Am Heart J. 2009;157:562e1-562e9.
28. Gurbel PA, Bliden KP, Butler K, et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation. 2010;121:1188-1199.
29. Cannon CP, Harrington RA, James S, et al. Platelet Inhibition and Patient Outcomes Investigators. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet. 2010;375:283-293.